Claim and source comparison

Comparison scope: Tiev 1999 abstract and ARCALION product information sections 4.1–4.8 and 5.2. Not a complete clinical or independent medical review.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human randomized controlled trial

Tiev 1999: A total of 326 patients with chronic postinfectious fatigue were randomized to 400 mg/day, 600 mg/day sulbutiamine or placebo for 28 days; 315 completed. Overall fatigue outcomes did not differ significantly between groups.

The day-7 signal in women receiving 600 mg did not persist at day 28. A subgroup finding is not overall efficacy or motivation/cognitive benefit in healthy people; study quantities are not a personal escalation protocol.

Source 1 · Abstract read

Official safety summary

French ARCALION information specifies 400–600 mg/day for adults for at most 4 weeks. This does not validate 800 mg/day for cognition or online cycling protocols. Persistent fatigue requires medical assessment.

A specific medicine's authorization text is not permission in every country/product, efficacy in healthy people or a personal prescription. It specifies no use in children/adolescents, avoidance in pregnancy and no use during breastfeeding.

Source 2 · Official summary read

Official safety summary

ARCALION product information reports peak blood levels at 1–2 hours and a half-life of approximately 5 hours.

Five hours is only an educational model in the source context; it is not brain concentration, onset or duration of effect. A one-compartment curve does not determine personal redosing intervals, accumulation or schedules.

Source 2 · Official summary read

Official safety summary

ARCALION information states that no specific interaction study was performed; it lists increased thiamine excretion with diuretics and possible enhancement of neuromuscular blockers. Agitation, headache, tremor, nausea/vomiting, rash and malaise are uncommon; stomach pain/diarrhea have unknown frequency.

Warnings for this product are not established interactions for every supplement or every antidepressant/alcohol combination. Missing studies do not establish safety; do not change medicines or timing yourself. Allergy and excipient cautions are product-specific.

Source 2 · Official summary read

Our evidence and source methodology

Sulbutiamine: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

Sulbutiamine is a synthetic thiamine derivative studied for fatigue. Motivation or cognitive enhancement in healthy people is not established; a drug authorization does not validate every proposed use.

Clinical Trials

Tiev 1999: A total of 326 patients with chronic postinfectious fatigue were randomized to 400 mg/day, 600 mg/day sulbutiamine or placebo for 28 days; 315 completed. Overall fatigue outcomes did not differ significantly between groups.

The day-7 signal in women receiving 600 mg did not persist at day 28. A subgroup finding is not overall efficacy or motivation/cognitive benefit in healthy people; study quantities are not a personal escalation protocol.

French ARCALION information specifies 400–600 mg/day for adults for at most 4 weeks. This does not validate 800 mg/day for cognition or online cycling protocols. Persistent fatigue requires medical assessment.

A specific medicine's authorization text is not permission in every country/product, efficacy in healthy people or a personal prescription. It specifies no use in children/adolescents, avoidance in pregnancy and no use during breastfeeding.

ARCALION product information reports peak blood levels at 1–2 hours and a half-life of approximately 5 hours.

Five hours is only an educational model in the source context; it is not brain concentration, onset or duration of effect. A one-compartment curve does not determine personal redosing intervals, accumulation or schedules.

ARCALION information states that no specific interaction study was performed; it lists increased thiamine excretion with diuretics and possible enhancement of neuromuscular blockers. Agitation, headache, tremor, nausea/vomiting, rash and malaise are uncommon; stomach pain/diarrhea have unknown frequency.

Warnings for this product are not established interactions for every supplement or every antidepressant/alcohol combination. Missing studies do not establish safety; do not change medicines or timing yourself. Allergy and excipient cautions are product-specific.

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Sources

  1. Tiev KP, et al. (1999). Treatment of chronic postinfectious fatigue: randomized double-blind study of two doses of sulbutiamine (400–600 mg/day) versus placebo. La Revue de médecine interne, 20(10), 912–918. PubMed · PMID 10573727
  2. ANSM · Base de Données Publique des Médicaments. ARCALION 200 mg, comprimé enrobé: Résumé des caractéristiques du produit. https://base-donnees-publique.medicaments.gouv.fr/medicament/64384738/extrait ANSM · Base de Données Publique des Médicaments

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions